21Shares updates its Injective ETF filing: TINJ, Nasdaq and staking
21Shares filed an amended S-1 for its Injective ETF with the SEC. The preliminary prospectus names the proposed Nasdaq ticker TINJ, the FTSE Injective Index and discretionary staking subject to legal conditions; the fund is not yet available for sale.
21Shares has updated the filing for an ETF designed to track Injective's native asset, INJ. Three details stand out in the document: Nasdaq, the TINJ ticker and staking subject to conditions.
What the filing says
Amendment No. 1 to the S-1 for the 21Shares Injective ETF entered the SEC system on 18 September. The document says the fund aims to track INJ through the FTSE Injective Index and reflect that performance after expenses.
The proposed exchange is Nasdaq and the proposed ticker is TINJ. The fund would hold INJ directly and says it does not seek to use leverage or derivatives.
What the staking language means
The filing says the sponsor may stake a portion of the fund's INJ if it determines that doing so would not create undue legal or regulatory risk. The aim would be to reflect staking rewards in the fund's performance.
The important word is "may." Staking is not described as an automatic feature. It depends on the sponsor's assessment and legal conditions including the fund's tax status.
Risks and common confusion
Biggest uncertainty The registration is not yet effective, and neither a trading date nor actual use of staking has been confirmed.
- A filing is not an SEC approval. The document says the information is incomplete and shares cannot be sold until the registration becomes effective.
- TINJ is not yet a live ETF ticker. It is the proposed ticker in the filing.
- Staking is not guaranteed. Its use depends on the sponsor's legal and regulatory assessment.
- An ETF does not remove INJ price risk. The product is designed to track INJ, so losses may also be reflected in its shares.
What comes next
The next milestones are whether the registration becomes effective, publication of a final prospectus, a trading start date and the final staking structure. For now this is an amended filing, not a launch announcement.
This article is not investment advice.
: SEC EDGAR: 21Shares Injective ETF, Amendment No. 1 to Form S-1
Sources
This article rests on the sources below. Whether each has a permanent copy is stated next to it.
- #1
The amended preliminary S-1 prospectus for the 21Shares Injective ETF dated 18 September 2026.
sec.gov· no permanent copy· no screenshot· cited 6 times in the text
Evidence chain: 1 sources
Tweets get deleted, sites go down. Below is whether a durable copy exists for each source.
Sources (1)
- #1
The amended preliminary S-1 prospectus for the 21Shares Injective ETF dated 18 September 2026.
“The information in this Preliminary Prospectus is not complete and may be changed.”
sec.gov/Archives/edgar/data/2061622/000121390026101489/ea0304701-s1a1_21shares.htm- no durable copy: if the source disappears, this claim loses its basis
- no screenshot captured